Lupus & antiphospholipid syndrome
Evaluating the real-world effectiveness of belimumab in patients with SLE using SLE-related laboratory values and rheumatoid arthritis-derived disease activity measures: RAPID3, swollen joint count and tender joint count
Authors' conclusion
In this real-world effectiveness study, belimumab therapy for SLE resulted in clinically meaningful improvements in rheumatoid arthritis-derived disease activity measures within 3 months of treatment, with patients who remained on belimumab therapy experiencing improvement even up to 24 months of observation.
Study context
- Population
- Adult patients with SLE who initiated intravenous belimumab between 1 January 2012 and 3 December 2019, with 12 months of pre-index and 24 months of post-index clinical activity21.0%–52.1% analysed per measure
- Participants
- 495 patients
- Outcome
- Time to first improvement of MID for RAPID3, Patient Pain Index (PPI), swollen joint count, tender joint count (TJC), complement C3 and C4 and anti-dsDNA antibodies
- Follow-up
- On-treatment up to 24 months
Methodological detailsreal-world, US electronic medical record data (United Rheumatology Normalised Integrated Community Evidence (UR-NICE) database)
- Real-world
- US electronic medical record data (UR-NICE database)
Main finding
As reported in the abstract
6 months
Achieved minimally important difference (MID) in RAPID3 after 6 months
52.3%
Achieved MID in Patient Pain Index (PPI) after 6 months
55.3%
Observational data: associations, not effects.
Secondary outcomes
Outcome measure trajectories up to 24 months
- Improved disease activity with belimumab, particularly in RAPID3, tender joint count (TJC) and laboratory values
Original publication
Evaluating the real-world effectiveness of belimumab in patients with SLE using SLE-related laboratory values and rheumatoid arthritis-derived disease activity measures: RAPID3, swollen joint count and tender joint count. Lupus Sci Med. Published 3 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →